




RFP-PD-2013-002

Intent to Apply (ITA)




A total of 23 eligible ITA forms were received. A breakdown of eligible ITA forms by disease, intervention and development stage is shown below: *



* One or more ITA included multiple diseases, interventions and/or development stages in the scope.

Full Proposal

A total of 18 eligible proposals were received. A breakdown of eligible proposals by disease, intervention and development stage is shown below:*



* One or more proposal included multiple diseases, interventions and/or development stages in the scope.

Award Notification

The following four projects were awarded funding.

Project Title	Collaboration Partners	Disease	Intervention	Development Stage	Total Amount
Development of rhPIV2 as a Potential New TB Vaccine Candidate	1. National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN) 2. Create Vaccine Co., Ltd (Create) 3. Aeras	TB	Vaccine	Pre-clinical	¥297,626,000
Anti-Wolbachia targeted macrofilaricidal drug discovery-lead optimization of lead series chemotypes to deliver novel pre-clinical candidates	1. Liverpool School of Tropical Medicine 2. Eisai Ltd., 3. University of Liverpool	Onchocerciasis, lymphatic filariasis	Drug	Pre-clinical	¥109,316,675
Development and registration of a new praziquantel pediatric formulation for the treatment of schistosomiasis	1. TI Pharma 2. Merck KGaA, 3. Astellas Pharma Inc., 4. Swiss Tropical and Public Health Institute	Schistosomiasis	Drug	Clinical Ph 1	¥186,489,892
A new treatment for Chagas disease	1. DNDi 2. Eisai Co., Ltd.	Chagas disease	Drug	Clinical Ph 1	¥384,089,264